Phospho-CBL (Tyr700) Antibody

What is the CBL protein and what role does Tyr700 phosphorylation play?

CBL proteins are a family of ubiquitin protein ligases (E3s) that negatively regulate signaling by targeting activated tyrosine kinases for degradation. While CBL proteins are ubiquitously expressed (except for CBL-c which is specific to epithelial cells), their activity is tightly regulated through phosphorylation events . Tyrosine 700 (Tyr700) is one of the key phosphorylation sites that modulates CBL function and interactions with downstream effectors, particularly in response to receptor tyrosine kinase activation. Tyr700 phosphorylation affects CBL's ability to interact with SH2 and SH3 domain-containing proteins, thereby influencing its role in signal transduction pathways .

How does a Phospho-CBL (Tyr700) antibody specifically detect this modification?

Phospho-CBL (Tyr700) antibodies are designed using synthetic phosphopeptides corresponding to amino acid residues surrounding tyrosine 700 in human c-CBL. This sequence is highly conserved across species including human, mouse, and rat . The antibodies undergo rigorous validation to ensure they specifically recognize the phosphorylated form of Tyr700 and not unphosphorylated CBL or other phosphorylation sites. During validation, antibodies are typically tested on samples such as pervanadate-treated Jurkat cells (positive control) versus untreated cells (negative control) to confirm specificity . The monoclonal antibody clone M161, for example, was generated from a synthetic phosphopeptide coupled to KLH corresponding specifically to the amino acid residues surrounding tyrosine 700 .

What are the optimal conditions for using Phospho-CBL (Tyr700) antibody in Western blotting?

For Western blotting applications, Phospho-CBL (Tyr700) antibodies are typically used at a dilution of 1:1000, though optimal dilutions should be determined empirically by each researcher . When performing Western blotting:

• Prepare cell lysates from appropriate positive control samples (e.g., pervanadate-treated cells that induce tyrosine phosphorylation).

• Load 20-40 μg of total protein per lane on SDS-PAGE gels.

• Transfer proteins to nitrocellulose or PVDF membranes.

• Block membranes with appropriate blocking buffer (typically 5% BSA in TBST).

• Incubate with primary antibody overnight at 4°C.

• Wash and incubate with HRP-conjugated secondary antibody.

• Develop using enhanced chemiluminescence detection.

The target protein should appear at approximately 120 kDa . For normalization purposes, stripping and reprobing with total CBL antibody is recommended to assess the ratio of phosphorylated to total protein.

How can I detect multiple phosphorylation sites on CBL simultaneously?

To investigate the relationship between multiple phosphorylation sites on CBL (such as Tyr700, Tyr731, and Tyr774), researchers can employ several approaches:

• Sequential immunoblotting: Strip and reprobe membranes with antibodies against different phosphorylation sites. This requires careful validation that stripping does not affect epitope detection.

• Parallel immunoblotting: Run multiple identical gels and probe each with a different phospho-specific antibody.

• Immunoprecipitation-based approach: As demonstrated in studies examining CBL mutants, researchers can overexpress tagged CBL proteins (WT or mutants), perform immunoprecipitation, and then analyze phosphorylation status of multiple sites. For example, research has shown that CBL mutants (CBL-70Z and CBL-Y371S) display enhanced phosphorylation at multiple tyrosine residues, particularly Y731, compared to wild-type CBL .

This multi-site analysis is crucial for understanding the interdependence of different phosphorylation events and their combined effects on CBL function.

How does CBL phosphorylation status change in disease models, particularly in myeloproliferative neoplasms?

Research on CBL mutations in myeloproliferative neoplasms has revealed important insights into how phosphorylation patterns are altered in pathological conditions. Studies have shown that E3-inactive CBL mutants identified in these neoplasms display enhanced phosphorylation at multiple tyrosine residues, including Tyr700, Tyr731, and Tyr774 .

In particular, CBL-70Z and CBL-Y371S mutants showed significantly enhanced phosphorylation at Y731 compared to wild-type CBL when expressed in HEK293 cells . These phosphorylation changes appear to affect the interaction of CBL with binding partners like CIN85, potentially rewiring the CBL interactome to promote oncogenesis.

To investigate such changes, researchers can:

• Express wild-type and mutant CBL in appropriate cell models

• Analyze phosphorylation status using phospho-specific antibodies

• Correlate phosphorylation changes with protein-protein interactions and downstream signaling events

• Use phosphorylation site mutants (Y700F, Y731F, etc.) to assess the functional importance of specific phosphorylation events

How can I determine if Tyr700 phosphorylation affects CBL's E3 ligase activity?

To investigate the relationship between Tyr700 phosphorylation and CBL's E3 ligase function, researchers can employ several experimental approaches:

• In vitro ubiquitination assays: Compare the E3 ligase activity of CBL proteins with varying phosphorylation states at Tyr700 (using phosphomimetic mutations or in vitro phosphorylation).

• Structure-function analysis: Use Y700F (non-phosphorylatable) or Y700E/D (phosphomimetic) mutations to assess how phosphorylation affects CBL's ability to ubiquitinate target proteins.

• Substrate degradation assays: Monitor the degradation rates of known CBL substrates (e.g., EGFR) in the presence of wild-type versus phosphorylation site mutants.

• Correlation studies: Compare Tyr700 phosphorylation status with ubiquitination activity in various cell stimulation conditions.

This is particularly important given that CBL proteins are known to ubiquitinate activated EGFR and target it for degradation, and phosphorylation events may regulate this process .

What are the best positive and negative controls for validating Phospho-CBL (Tyr700) antibody specificity?

To ensure antibody specificity, appropriate controls are essential:

Positive controls:

• Jurkat cells treated with pervanadate (a protein tyrosine phosphatase inhibitor that enhances phosphorylation)

• Cells stimulated with growth factors known to induce CBL phosphorylation

• Cells expressing constitutively active tyrosine kinases that phosphorylate CBL

Negative controls:

• Untreated cells (baseline phosphorylation)

• Cells expressing Y700F CBL mutant (non-phosphorylatable at this site)

• Phosphatase-treated lysates to remove phosphorylation

• Peptide competition assays using the phosphopeptide immunogen

These controls help confirm that the observed signal is specific to phosphorylated Tyr700 and not due to cross-reactivity with other phosphorylation sites or proteins.

What normalization methods are recommended for quantifying Phospho-CBL (Tyr700) levels in experimental samples?

Several normalization strategies can be employed when quantifying Phospho-CBL (Tyr700) levels:

• Total CBL normalization: The most direct approach is to normalize phospho-CBL signals to total CBL protein levels. This requires stripping and reprobing membranes or running parallel blots with total CBL antibody .

• Internal controls: Include GAPDH or other housekeeping proteins as loading controls. Some cell-based ELISA systems specifically incorporate anti-GAPDH antibodies as internal positive controls .

• Cell density normalization: For cell-based assays, Crystal Violet staining can be used to determine cell density, allowing adjustment for plating differences .

• Phosphorylation-specific normalization: When studying phosphorylation dynamics, normalization to non-phosphorylated counterpart antibodies helps assess relative phosphorylation states .

For accurate quantification, densitometric analysis of Western blots should be performed using appropriate software, with background subtraction and linear range validation.

How should experiments be designed to investigate the relationship between different CBL phosphorylation sites?

To examine the interplay between multiple phosphorylation sites on CBL (Tyr700, Tyr731, Tyr774), consider the following experimental design:

• Generate phosphorylation site mutants: Create single (Y700F), double (Y700F/Y731F), and triple (Y700F/Y731F/Y774F) mutants to assess the interdependence of phosphorylation events .

• Time-course experiments: Monitor the temporal dynamics of phosphorylation at different sites following stimulation to determine sequential ordering of phosphorylation events.

• Kinase inhibitor studies: Use specific inhibitors to identify the kinases responsible for phosphorylation at each site.

• Binding partner analysis: Assess how different phosphorylation patterns affect interactions with known CBL binding partners, such as CIN85 .

• Functional assays: Determine how each phosphorylation site contributes to CBL-mediated functions such as receptor downregulation, protein ubiquitination, and signal transduction.

This comprehensive approach can reveal how different phosphorylation events cooperate or antagonize each other in regulating CBL function.

What cell models and stimulation conditions are optimal for studying physiologically relevant Tyr700 phosphorylation?

To study CBL Tyr700 phosphorylation under physiologically relevant conditions:

Cell models:

• Hematopoietic cell lines (e.g., Jurkat) where CBL function is well-characterized

• Cell lines relevant to specific research questions (e.g., epithelial cells for EGFR signaling)

• Primary cells from normal and disease contexts

• Patient-derived samples for clinical relevance

Stimulation conditions:

• Receptor tyrosine kinase ligands (EGF, PDGF, etc.) at physiological concentrations

• Immune receptor stimulation (T-cell or B-cell receptor activation)

• Cytokine stimulation relevant to the biological context being studied

• Low dose and time-course studies to capture transient phosphorylation events

Inhibitor studies:

• Specific kinase inhibitors to identify responsible kinases

• Phosphatase inhibitors (with caution) to stabilize phosphorylation for detection

Combining these approaches allows for a more complete understanding of the biological contexts in which Tyr700 phosphorylation occurs and its functional consequences.

How can researchers differentiate between direct and indirect effects on CBL Tyr700 phosphorylation?

Distinguishing direct from indirect effects on CBL Tyr700 phosphorylation requires rigorous experimental approaches:

• In vitro kinase assays: Using purified CBL protein and candidate kinases to determine direct phosphorylation capability.

• Kinase inhibitor specificity controls: Employ multiple inhibitors with different specificity profiles to triangulate the responsible kinase.

• Phosphorylation site mapping: Mass spectrometry analysis to confirm Tyr700 phosphorylation and identify other modified residues.

• Kinase knockdown/knockout validation: Genetic approaches to eliminate candidate kinases and assess effects on Tyr700 phosphorylation.

• Temporal resolution studies: High-resolution time-course experiments to establish cause-effect relationships.

• Computational modeling: Integrating experimental data into signaling network models to predict direct versus indirect effects.

These approaches help differentiate between direct kinase action on Tyr700 versus indirect effects mediated through intermediate signaling components.

What are the potential pitfalls in interpreting CBL phosphorylation data in mutational studies?

When conducting and interpreting CBL mutational studies, researchers should be aware of several potential complications:

• Structural perturbations: Mutations intended to block phosphorylation (e.g., Y700F) may alter protein folding or domain interactions, leading to effects beyond simply preventing phosphorylation.

• Interdependence of modifications: As demonstrated with CBL-Y371S mutants, alterations at one site can affect phosphorylation at other sites (e.g., Y700, Y731, Y774) , complicating interpretation.

• Expression level artifacts: Overexpression systems may lead to non-physiological phosphorylation patterns or protein interactions.

• Cell type-specific effects: Results from one cell system (e.g., HEK293 cells) may not translate to other cell types due to differences in kinase/phosphatase expression.

• Temporal considerations: Mutation effects on phosphorylation dynamics may be missed in single-timepoint experiments.

• Antibody cross-reactivity: Ensure phospho-specific antibodies do not cross-react with other phosphorylation sites, especially in mutated proteins where epitope accessibility may change.

Careful experimental design with appropriate controls and validation across multiple experimental systems helps mitigate these pitfalls.